AstraZeneca closed at $158.61, up 1.33% and ahead of the S&P 500's 0.58% gain. The company is scheduled to report earnings on October 30, 2026, with analysts expecting EPS of $2.16, a 9.24% decline from the year-earlier quarter, and revenue of $16.07 billion, up 5.82%. For the full year, consensus estimates project earnings of $9.37 per share and revenue of $63.12 billion, changes of +2.29% and +7.46% respectively. AstraZeneca currently carries a Zacks Rank of #3 (Hold), and its Forward P/E of 16.71 is a discount to the industry average of 22.46.
AstraZeneca PLCEarnings preview shows expected EPS decline of 9.24% YoY but revenue growth of 5.82%, with a Hold rating and discounted Forward P/E.
